ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

2025Äê11ÔÂ9ÈÕ£¬£¬£¬£¬£¬£¬È«Çò°©Ö¢ÃâÒßÖÎÁÆÁìÓò¼«¾ßÓ°ÏìÁ¦µÄ¹ú¼ÊѧÊõÊ¢»á——µÚ40½ì°©Ö¢ÃâÒßÖÎÁÆѧ»á£¨SITC£©Äê»áÔÚÃÀ¹úÔ²ÂúÂäÄ»¡£¡£¡£¡£¡£ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼°ÆäÃÀ¹ú¹«Ë¾Chantibody Therapeutics×é³ÉµÄÖÐÃÀЭͬÍŶÓÔÚ¹ú¼ÊѧÊõƽ̨ÉÏÐû²¼ÁËCT111ºÍCT224Á½¿îÁ¢ÒìÃâÒßÖÎÁÆÒ©ÎïµÄÁÙ´²Ç°Êý¾Ý¡£¡£¡£¡£¡£

ÕâÁ½¿îÒ©Îï¾ùÔ´×Ô½üÆÚÕ¶»ñÖÐÃÀ˫רÀûµÄµÚËÄ´úÄÉÃ׿¹ÌåVHHMAb®Æ½Ì¨£¬£¬£¬£¬£¬£¬ÒԓרÀûƽ̨+¹ÜÏß¿ª·¢”µÄЧ¹ûÂäµØ£¬£¬£¬£¬£¬£¬ÇåÎúÕ¹ÏÖÁË´Ó»ù´¡Ñо¿µ½Ó¦ÓÃת»¯µÄ¸ßЧ·¾¶£¬£¬£¬£¬£¬£¬ÎªÊµÌåÖ×ÁöÖÎÁÆ´øÀ´¾ßÓвî±ð»¯ÓÅÊƵĽâ¾ö¼Æ»®¡£¡£¡£¡£¡£

CT111£ºÈýÌØÒìÐÔ¿¹ÌåʵÏÖÈýÖØ»úÖÆЭͬ¿¹°© ÆƽâʵÌåÁöÖÎÁÆÆ¿¾±

ÕªÒª±àºÅ£º976

ÕªÒªÎÊÌ⣺CT111, a PD-1 x CTLA-4 x VEGF trispecific antibody, demonstrates potent anti-tumor efficacy through synergistic immune checkpoint blockade and VEGF inhibition with cooperative avidity

CT111ÊÇÒ»¿î°ÐÏòPD-1¡¢CTLA-4ºÍVEGFµÄÈýÌØÒìÐÔ¿¹Ì壬£¬£¬£¬£¬£¬Í¨¹ý¼òµ¥È«VHH·Ö×ÓʵÏÖÒÖÖÆÖ×ÁöѪ¹ÜÌìÉúЭͬ¼¤»îTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬´ú±íÏÂÒ»´úÃâÒßÖÎÁƵÄÆ«Ïò¡£¡£¡£¡£¡£¸ÃÑо¿ÓÉChantibodyǣͷ£¬£¬£¬£¬£¬£¬ÖÐÃÀÍŶӷֹ¤Ð­×÷¸ßЧÍê³É¹¥¹Ø¡£¡£¡£¡£¡£

Åä¾°ÏÈÈÝ£ºPD-1¡¢CTLA-4ºÍVEGFÊÇÖ×ÁöÃâÒßÖÎÁÆÖÐÒÑ»ñÁÙ´²ÑéÖ¤µÄÒªº¦°Ðµã£¬£¬£¬£¬£¬£¬ÈýÕßÔÚ¿¹Ö×ÁöÃâÒßÑ­»··´Ó¦ÖÐÊ©Õ¹»¥²¹×÷Óᣡ£¡£¡£¡£ÏÖÔÚË«ÌØÒìÐÔ¿¹ÌåºÍ¶à°ÐµãÍŽáÖÎÁÆËäÒÑÕ¹ÏÖÁÙ´²Ç±Á¦£¬£¬£¬£¬£¬£¬µ«ÔÚ¿¹Ö×ÁöÁÆЧһÁ¬ÐÔºÍ×ÜÌåÉúÑÄ»ñÒæÉÏÈÔÓвî±ð¡£¡£¡£¡£¡£CT111ͨ¹ý¶àÌØÒìÐÔ¿¹ÌåµÄЭͬÍŽáÌØÕ÷£¬£¬£¬£¬£¬£¬½«¿¹PD-1£¨»Ö¸´Ð§Ó¦TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾»îÐÔ£©¡¢¿¹CTLA-4£¨TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Æô¶¯/ÔöÖ³£©ÒÔ¼°¿¹VEGF£¨ÒÖÖÆÖ×ÁöѪ¹ÜÌìÉú£©¹¦Ð§¼¯ÓÚÒ»Ì壬£¬£¬£¬£¬£¬ÓÐÍûʵÏÖ¸üÓŵÄÉúÎïѧЭͬЧӦÓëÁÙ´²»ñÒæ¡£¡£¡£¡£¡£

·Ö×ÓÉè¼ÆÓë»úÖÆ£º

½èÖú¶àÑùÐÔ¿¹Ìå·¢Ã÷ºÍAIÉè¼ÆÄ£¿£¿£¿£¿£¿é£¬£¬£¬£¬£¬£¬Ñз¢ÍŶÓÀֳɹ¹½¨³öË«¼ÛÈý°ÐµÄ¶Ô³Æ¶þ¾Û¿¹Ìå½á¹¹£¬£¬£¬£¬£¬£¬½«¿¹Ö×ÁöÌØÒìÐÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼¤»î£¨CTLA-4£©£¬£¬£¬£¬£¬£¬Ö×ÁöÒÖÖƺÍTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾½þÈó£¨VEGF£©£¬£¬£¬£¬£¬£¬ÒÔ¼°Ö×Áö΢ÇéÐε÷¿Ø£¨PD-1£©Èý´ó½¹µã»úÖƸßЧÈںϣ¬£¬£¬£¬£¬£¬Ðγɓ¹¥·À¼æ±¸”µÄЭͬ¿¹°©Ð§Ó¦¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÍâÊý¾Ý: 

CT111¹ØÓÚVEGFµÄ×è¶Ï»îÐÔ±ÈÆäËûVEGFË«¿¹ºÍÈý¿¹²úÆ·ºá¿ç4-5±¶£¬£¬£¬£¬£¬£¬¾ßÓÐPD-1£¬£¬£¬£¬£¬£¬CTLA-4ºÍVEGFÈý°ÐµãÉúÎïѧ»îÐÔºÍÁÙ´²¼ÁÁ¿¸ß¶ÈƽºâµÄÓÅÊÆ£¬£¬£¬£¬£¬£¬¿ÉÒÔ½â¾ö»ñÅúVEGFµ¥¿¹ÁÙ´²¼ÁÁ¿£¨10-15mg/kg£©Áè¼ÝPD-1»òCTLA-4µ¥¿¹¹ØÓÚË«¿¹Èý¿¹¼ÁÁ¿Ñ¡ÔñµÄÄæ¾³£¬£¬£¬£¬£¬£¬Ó뾺ƷÏà±È¾ßÓиüÇ¿µÄ²úÆ·ÓÅÊƺÍÁÙ´²ÓÅÊÆ£¬£¬£¬£¬£¬£¬¿ÉÍØ¿íÇå¾²ÓÐÓõÄÖÎÁÆ´°¿Ú¡£¡£¡£¡£¡£CT111¸ü½øÒ»²½Õ¹ÏÖ³öÆæÒìµÄ“Ç׺ÍÁ¦Ð­Í¬Ð§Ó¦”£¬£¬£¬£¬£¬£¬ÓëVEGFÍŽáºó£¬£¬£¬£¬£¬£¬¼ÈÄÜÏÔÖøÔöÇ¿¶ÔPD-1£¨129±¶£©ºÍCTLA-4£¨15±¶£©µÄÍŽáºÍ×è¶ÏÄÜÁ¦£¬£¬£¬£¬£¬£¬ÓÖ×èÖ¹Á˾ºÆ·±¬·¢µÄ¶à¾ÛÌå·ÇÌØÒìÍŽáÕ÷Ïó£¬£¬£¬£¬£¬£¬ÊµÏÖÁË1+1+1 > 3µÄ¾«×¼Ð­Í¬¿¹°©Ð§¹û¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÄÚÊý¾Ý: 

ÔÚÌåÄÚʵÑéÖУ¬£¬£¬£¬£¬£¬µÍ¼ÁÁ¿CT111ÔÚ¶àÖÖÖ×ÁöÄ£×ÓÖÐʵÏÖÁ˳¤ÆÚµÄÖ×ÁöÏûÍ˺ÍÃâÒßÓ°Ïó£¬£¬£¬£¬£¬£¬ÁÆЧÏÔÖøÓÅÓÚÁÙ´²±ê¸Ë¿¹Ìå¡£¡£¡£¡£¡£¶ÔHCC827Ö×Áö×éÖ¯µÄÆÊÎöÏÔʾ£¬£¬£¬£¬£¬£¬CT111ÖÎÁƺóÏà¶ÔPD-1/VEGFË«¿¹¾ºÆ·Õë¶ÔÖ×ÁöɱÉ˵ĻCD8+ TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÊýÄ¿ÔöÌí£¬£¬£¬£¬£¬£¬ÃâÒßÒÖÖƵĵ÷ÀíÐÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¨Treg£©ÊýÄ¿ïÔÌ­£¬£¬£¬£¬£¬£¬Åú×¢CT111ÖÐCTLA-4×è¶Ï¹¦Ð§¹ØÓÚ¿¹Ö×ÁöµÄÏìÓ¦ºÍ³¤ÆÚÆðµ½ÁËÒªº¦×÷Óᣡ£¡£¡£¡£³ýÁËÏÔÖøµÄÁÆЧ£¬£¬£¬£¬£¬£¬ÓÉÓÚCT111ȱ·¦FcЧӦ¹¦Ð§£¬£¬£¬£¬£¬£¬×èÖ¹ÁËÕý³£×éÖ¯ÖÐTregµÄÏû³ý£¬£¬£¬£¬£¬£¬ÎªÆäÃâÒßÇå¾²ÐÔÌṩÁËÖ÷Òª°ü¹Ü¡£¡£¡£¡£¡£

Ñо¿ÍŶÓÖ¸³ö£¬£¬£¬£¬£¬£¬CT111ͨ¹ýЭͬ×÷ÓÃÔöÇ¿Ö×ÁöÌØÒìTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÔöÖ³£¬£¬£¬£¬£¬£¬½þÈóºÍ¼¤»î£¬£¬£¬£¬£¬£¬ÓÅ»¯Èý°ÐµãÍŽáºÍÉúÎïѧ»îÐÔµÄЭµ÷ƽºâ£¬£¬£¬£¬£¬£¬ÊµÏÖÖ×Áö΢ÇéÐÎÄÚ»îÐÔºÍÁÙ´²Çå¾²ÓÐÓÃÖÎÁÆ´°¿ÚµÄ·Å´ó¡£¡£¡£¡£¡£ÕâЩ·¢Ã÷ΪCT111½øÈëʵÌåÁöÁÙ´²¿ª·¢£¬£¬£¬£¬£¬£¬ÓÈÆäÊÇÕë¶ÔPD-1ÄÍÒ©»¼ÕßµÄÖÎÁƺÍÐÂÒ»´úPD-1¶à¿¹Ò©ÎïµÄ¿ª·¢ÌṩÁ˼áʵÒÀ¾Ý¡£¡£¡£¡£¡£

CT224£ºË«±íλTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÏνÓÆ÷¼æ¹ËÁÆЧÓëÇå¾²£¬£¬£¬£¬£¬£¬Í»ÆƽáÖ±³¦°©ÖÎÁƾÖÏÞ

ÕªÒª±àºÅ£º958

ÕªÒªÎÊÌ⣺CT224: A biparatopic VHH-based CDH17×CD3 T cell engager with optimized safety and efficacy for colorectal cancer

CT224ÊÇÒ»¿î°ÐÏòCDH17Ë«»¥²¹±íλµÄCD3 TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÏνÓÆ÷£¨TCE£©¡£¡£¡£¡£¡£ ͨ¹ýË«±íλÍŽáʵÏÖ¶ÔÖ×ÁöµÄ¸ßÌØÒìÐÔ궨£¬£¬£¬£¬£¬£¬²¢Ê¹ÓÃɸѡÓÅ»¯µÄµÍÇ׺ÍÁ¦¿¹CD3ÄÉÃ׿¹Ìå½µµÍ¹Å°åTCEµÄ¶¾ÐÔΣº¦¡£¡£¡£¡£¡£

CT224µÄÁ¢ÒìÉè¼ÆÖ¼ÔÚÆƽâ¹Å°åTCEÔÚʵÌåÁöÖÎÁÆÖГÁÆЧȱ·¦¡¢¶¾ÐÔÆ«¸ß”µÄÍ´µã£¬£¬£¬£¬£¬£¬Îª½â¾öTCEÔÚʵÌåÁöÖÎÁÆÖеÄÌôÕ½ÌṩÐÂÕ½ÂÔ¡£¡£¡£¡£¡£¸ÃÑо¿Í¬ÑùÓÉChantibody Therapeutics¹«Ë¾Ç£Í·£¬£¬£¬£¬£¬£¬ÖÐÃÀÍŶӷֹ¤Ð­×÷¸ßЧÍê³É¹¥¹Ø¡£¡£¡£¡£¡£

Åä¾°ÏÈÈÝ£º

½áÖ±³¦°©ÊÇÈ«Çò¹æÄ£ÄÚÖØ´óµÄδ±»Öª×ãÒ½ÁÆÐèÇó£¬£¬£¬£¬£¬£¬¸ÆÕ³ÂÑ°×-17£¨CDH17£©ÔÚ´ó´ó¶¼½áÖ±³¦°©Öи߱í´ï£¬£¬£¬£¬£¬£¬Óë²»Á¼Ô¤ºó¼°ÉúÑÄÆÚËõ¶ÌÏà¹Ø¡£¡£¡£¡£¡£ÔÚÕý³£³¦µÀ×éÖ¯ÖУ¬£¬£¬£¬£¬£¬CDH17¾ÖÏÞÓÚϸÃÜÅþÁ¬£¬£¬£¬£¬£¬£¬¶øÔÚÖ×ÁöÖÐÒì³£¸ß±í´ïÇÒ¶¨Î»¸Ä±ä£¬£¬£¬£¬£¬£¬Ê¹Æä³ÉΪÀíÏëµÄÖ×ÁöÖÎÁưе㡣¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬ÏÖÓÐTCEÔÚʵÌåÁöÖеÄÓ¦ÓÃÊÜÏÞÓڰеãÌØÒìÐÔȱ·¦¡¢CD3¿¹Ìå»îÐÔµ÷¿ØÄÑÌâ¼°Ö×Áö´©Í¸ÐÔ²îµÈÎÊÌâ¡£¡£¡£¡£¡£

·Ö×ÓÉè¼ÆÓë»úÖÆ£º

»ùÓÚµÚËÄ´úÄÉÃ׿¹ÌåVHHMAb®Æ½Ì¨£¬£¬£¬£¬£¬£¬Ñо¿ÍŶÓÀֳɻñµÃÁËÁýÕÖCDH17Æ߸ö°ûÍâÓòÇ׺ÍÁ¦²î±ðǧ±¶µÄCDH17 VHH¿¹Ìå¿â£¬£¬£¬£¬£¬£¬ÒÔ¼°¾ß±¸²î±ðCD3ÍŽá»îÐÔµÄCD3 VHH¿¹Ìå¿â¡£¡£¡£¡£¡£Ê¹ÓÃAIƽ̨Éè¼ÆÒÔ¼°¸ßͨÁ¿¹¦Ð§É¸Ñ¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬ÏµÍ³ÐԵĶÔCDH17Ë«±íλ¡¢CD3¿¹ÌåÑ¡ÔñÒÔ¼°LinkerÑ¡Ôñ£¬£¬£¬£¬£¬£¬¾ÙÐÐÉè¼ÆÓëÓÅ»¯¡£¡£¡£¡£¡£×îÖÕºòÑ¡·Ö×ÓCT224Õ¹ÏÖ³öǿЧµÄÖ×ÁöɱÉËÄÜÁ¦¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÍâÊý¾Ý£º

ÔÚCD8TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾½éµ¼µÄÌåÍâTDCCʵÑéÖУ¬£¬£¬£¬£¬£¬Ïà¹ØÓÚµ¥±íλ¿¹ÌåºÍARB202 £¨Benchmark£©£¬£¬£¬£¬£¬£¬Ë«±íλCT224Õ¹ÏÖ³öpM¼¶±ðµÄEC50£¬£¬£¬£¬£¬£¬Åú×¢Æä¾ß±¸¼«Ç¿µÄÖ×ÁöɱÉË»îÐÔ¡£¡£¡£¡£¡£ÔÚPBMCÎÞ°ÐÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¹²·õÓýʵÑéÖУ¬£¬£¬£¬£¬£¬Åä¾°TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¼¤»î¼°ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Òò×ÓÊÍ·Åˮƽ¼«µÍ£¬£¬£¬£¬£¬£¬ÌåÏÖ³öÓÅÒìµÄÇå¾²ÐÔ¡£¡£¡£¡£¡£CT224»¹¾ß±¸ÓÅÒìµÄ³ÉÒ©ÐÔÌØÕ÷£¬£¬£¬£¬£¬£¬°üÀ¨1g/LÒÔÉϵĸ߱í´ïÁ¿¡¢¸ß´¿»¯´¿¶È¡¢µÍ¶à·´Ó¦ÐÔ¼°ÓÅÒìµÄÈÈÎȹÌÐÔ£¨Tm¸ßÓÚ65¶È£©£¬£¬£¬£¬£¬£¬ÎªÆä½øÈëÁÙ´²¿ª·¢µÓÚ¨Á˼áʵ»ù´¡¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬CT224µÄ¿¹Ìå¿ÉÓëÈËÔ´¡¢Ê³Ð·ºï¼°ÊóÔ´CDH17½»Ö¯·´Ó¦£¬£¬£¬£¬£¬£¬ÎªÁÙ´²Ç°Ñо¿¼°×ª»¯Ó¦ÓÃÌṩÁ˱㵱¡£¡£¡£¡£¡£

ÁÙ´²Ç°ÌåÄÚÊý¾Ý£º

ÔÚPBMCÈËÔ´»¯Ð¡ÊóCOLO205Ö×ÁöÄ£×Ó£¬£¬£¬£¬£¬£¬ÒÔ¼°HSCÈËÔ´»¯Ð¡ÊóDLD1Ö×ÁöÄ£×ÓÖУ¬£¬£¬£¬£¬£¬CT224µÄÖ×ÁöÉú³¤ÒÖÖÆЧ¹û¾ùÓÅÓÚARB202£¨Benchmark£©£¬£¬£¬£¬£¬£¬²¢ÇҾ߱¸¼ÁÁ¿ÒÀÀµµÄÖ×ÁöÒÖÖÆЧ¹û¡£¡£¡£¡£¡£Í¬Ê±ÔÚʳзºïPKʵÑé̽Ë÷ÖУ¬£¬£¬£¬£¬£¬CT224Õ¹ÏÖ³öÀàIgGµÄ6-7Ìì°ëË¥ÆÚÌØÕ÷£¬£¬£¬£¬£¬£¬Åú×¢ÆäÔÚÈËÌåÄÚ¿ÉÄܾ߱¸ÓÅÒìµÄ¸øҩƵÂÊÓÅÊÆ¡£¡£¡£¡£¡£

Ñо¿½áÂÛÅú×¢£¬£¬£¬£¬£¬£¬CT224×÷ΪÐÂÐÍË«±íλCDH17×CD3 TCE£¬£¬£¬£¬£¬£¬¼æ¾ßǿЧ¿¹Ö×Áö»îÐÔÓëÓÅÒìÇå¾²ÐÔ£¬£¬£¬£¬£¬£¬ÆäС·Ö×ӳߴç¸üÓÐÀûÓÚÖ×Áö´©Í¸£¬£¬£¬£¬£¬£¬ÓÐÓýâ¾öÁËÏÖÓÐTCEÔÚʵÌåÁöÖÎÁÆÖеÄÒªº¦¾ÖÏÞ¡£¡£¡£¡£¡£Æä¿çÎïÖÖ·´Ó¦ÐÔ¡¢ÓÅÒìÒ©´ú¶¯Á¦Ñ§¼°³ÉÒ©ÐÔÌØÕ÷£¬£¬£¬£¬£¬£¬Ö§³ÖÆä×÷ΪÊ׿îÕë¶Ô½áÖ±³¦°©µÄË«±íλTCE¿ªÕ¹½øÒ»²½ÁÙ´²Ç°¿ª·¢¼°ÁÙ´²×ª»¯¡£¡£¡£¡£¡£

ÖÐÃÀЭͬ£º´ÓÊÖÒÕרÀû¹âÁÙ´²Ç±Á¦µÄ¸ßЧת»¯

“ÈôÊÇ˵µÚËÄ´úÄÉÃ׿¹Ìåƽ̨µÄÖÐÃÀ˫רÀûÊÇ‘ÐîÄÜ’£¬£¬£¬£¬£¬£¬ÄÇô´Ë´ÎSITCÐû²¼µÄ˫ҩЧ¹û¾ÍÊÇ‘ÊÍÄÜ’¡£¡£¡£¡£¡£”ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶­Ê³¤¼æCEOÇ®Æä¾ü½ÌÊÚÌåÏÖ£¬£¬£¬£¬£¬£¬Æ½Ì¨µÄAIÉè¼ÆÓë¸ßÌØÒìÐÔɸѡÓÅÊÆ£¬£¬£¬£¬£¬£¬ÈÃCT111µÄÈý°ÐµãЭͬ¡¢CT224µÄË«±íλ¾«×¼ÍŽá³ÉΪ¿ÉÄÜ£¬£¬£¬£¬£¬£¬¶øÖÐÃÀÍŶӵķֹ¤Ð­×÷Ôò¼ÓËÙÁËЧ¹ûÂäµØ——¼¯ÍÅÒÀÍи»ºñµÄÑòÍÕ×ÊÔ´ºÍ¿¹Ìå·¢Ã÷ÊÖÒÕÌṩ¶àÑù»¯¸ßÖÊÁ¿µÄµ¥°ÐÄÉÃ׿¹Ì壬£¬£¬£¬£¬£¬ChantibodyÒÀ¸½ÃÀ¹ú±¾ÍÁµÄ¿¹Ì幤³ÌÊÖÒÕÓÅÊƺͶ࿹²úÆ·¿ª·¢ÂÄÀúÖ÷¹¥·Ö×ÓÓÅ»¯ºÍ²úÆ·Íƽø£¬£¬£¬£¬£¬£¬ “ÊÖÒÕͬԴ¡¢ÓÅÊÆ»¥²¹”µÄģʽÈÃÁ¢ÒìЧÂʱ¶Ôö¡£¡£¡£¡£¡£

Chantibody×ܲá¢Ê×ϯ¿Æѧ¹ÙÐíÎķ岩ʿÔö²¹µÀ£¬£¬£¬£¬£¬£¬“×÷ΪÖÐÃÀЭͬ¿ª·¢µÄVHHMAb®Æ½Ì¨µÄÖÐÃÀ˫רÀûÊÚȨÒâÒåÖØ´ó£¬£¬£¬£¬£¬£¬Ëü²»µ«ÑéÖ¤ÁËÎÒÃǵײãÊÖÒÕµÄÔ­´´ÐÔÓë¹ú¼Ê¾ºÕùÁ¦£¬£¬£¬£¬£¬£¬¸üΪCT111¡¢CT224µÈºóÐø¹ÜÏßÒ©ÎïµÄÈ«Çò¿ª·¢µÓÚ¨ÁËÊÖÒÕ»ù´¡¡£¡£¡£¡£¡£´Ë´Î˫Ч¹ûÁÁÏàSITC£¬£¬£¬£¬£¬£¬Ö¤ÊµÎúÎÒÃǑƽ̨Ñз¢+¾«×¼×ª»¯’ģʽµÄÀֳɣ¬£¬£¬£¬£¬£¬Ò²Õ¹ÏÖÁËÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÓëChantibodyÔڰе㷢Ã÷¡¢¿¹Ì幤³Ì¼°ÁÙ´²Ç°Ñо¿È«Á´ÌõµÄЭͬÓÅÊÆ¡£¡£¡£¡£¡£½ÓÏÂÀ´£¬£¬£¬£¬£¬£¬ÎÒÃǽ«¼ÓËÙÍƽøÁ½¿îÒ©ÎïµÄÁÙ´²×ª»¯£¬£¬£¬£¬£¬£¬´òÔì¸ü¶àÈ«ÇòÊ×´´µÄÖ×ÁöÃâÒßÖÎÁƼƻ®¡£¡£¡£¡£¡£”

×÷ΪȫÇò°©Ö¢ÃâÒßÖÎÁÆÁìÓòµÄÖ÷ҪЭͬʵÁ¦£¬£¬£¬£¬£¬£¬ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÓëChantibodyʼÖÕ±ü³Ö“ÊÖÒÕͬԴ¡¢ÓÅÊÆ»¥²¹”µÄÑз¢ÀíÄ£¬£¬£¬£¬£¬ÒÀÍдӵײãƽ̨µ½Ò©Îï¹ÜÏßµÄÈ«¹¤ÒµÁ´½á¹¹£¬£¬£¬£¬£¬£¬Ò»Á¬Íƶ¯Ö×ÁöÖÎÁÆÊÖÒÕµÄÁ¢ÒìÍ»ÆÆ¡£¡£¡£¡£¡£´Ë´ÎÔÚSITCÄê»áͬ²½Õ¹Ê¾×¨Àûƽ̨ÓëÖØ°õÒ©ÎïЧ¹û£¬£¬£¬£¬£¬£¬²»µ«Õ¹ÏÖÁËÖÐÃÀЭͬÑз¢Ä£Ê½µÄ¸ßЧÐÔ£¬£¬£¬£¬£¬£¬¸üÒԓƽ̨»ñרÀû¡¢Ò©ÎïÏÔÁÆЧ”µÄË«ÖØÍ»ÆÆ£¬£¬£¬£¬£¬£¬ÎªÈ«ÇòÖ×ÁöÃâÒßÖÎÁƵÄÉú³¤×¢Èëж¯ÄÜ¡£¡£¡£¡£¡£